• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Ensysce Biosciences Inc.

    5/15/25 4:30:09 PM ET
    $ENSC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ENSC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    Ensysce Biosciences, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    293602504

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    293602504


    1Names of Reporting Persons

    Perceptive Advisors LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    86,666.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    86,666.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    86,666.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.7 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    293602504


    1Names of Reporting Persons

    Joseph Edelman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    86,666.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    86,666.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    86,666.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.7 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    293602504


    1Names of Reporting Persons

    Perceptive Life Sciences Master Fund, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    86,666.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    86,666.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    86,666.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.7 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Ensysce Biosciences, Inc.
    (b)Address of issuer's principal executive offices:

    7946 Ivanhoe Avenue, Suite 201, La Jolla, CA 92037
    Item 2. 
    (a)Name of person filing:

    The names of the persons filing this report (collectively, the "Reporting Persons") with respect to shares of Common Stock, par value $0.0001 per share (the "Common Stock") of Ensysce Biosciences, Inc. (the "Issuer") are: (i) Perceptive Advisors LLC ("Perceptive Advisors") (ii) Joseph Edelman ("Mr. Edelman") (iii) Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund")
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is: 51 Astor Place, 10th Floor, New York, NY 10003
    (c)Citizenship:

    Perceptive Advisors is a Delaware limited liability company. Mr. Edelman is a United States citizen. The Master Fund is a Cayman Islands corporation.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    293602504
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 of the cover pages to this Schedule 13G. The ownership percentages reported are based on 2,370,698 shares of Common Stock outstanding as of April 28, 2025, as reported in the Issuer's registration statement on Form S-3 filed with the Securities and Exchange Commission on May 2, 2025. The Master Fund directly holds 86,666 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and may be deemed to beneficially own such shares. Mr. Edelman is the managing member of Perceptive Advisors and may be deemed to beneficially own such shares.
    (b)Percent of class:

    Perceptive Advisors: 3.7% Mr. Edelman: 3.7% Master Fund: 3.7
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0

     (ii) Shared power to vote or to direct the vote:

    Perceptive Advisors: 86,666 Mr. Edelman: 86,666 Master Fund: 86,666

     (iii) Sole power to dispose or to direct the disposition of:

    Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0

     (iv) Shared power to dispose or to direct the disposition of:

    Perceptive Advisors: 86,666 Mr. Edelman: 86,666 Master Fund: 86,666

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Perceptive Advisors LLC
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:05/15/2025
     
    Joseph Edelman
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman
    Date:05/15/2025
     
    Perceptive Life Sciences Master Fund, Ltd.
     
    Signature:/s/ Joseph Edelman
    Name/Title:Joseph Edelman, Managing Member
    Date:05/15/2025
    Get the next $ENSC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ENSC

    DatePrice TargetRatingAnalyst
    11/30/2021$4.00Buy
    Lake Street
    More analyst ratings

    $ENSC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Gower Bob G bought $182,350 worth of shares (379,300 units at $0.48), increasing direct ownership by 50% to 1,132,395 units

      4 - Ensysce Biosciences, Inc. (0001716947) (Issuer)

      3/2/23 3:45:52 PM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Gower Bob G bought $500,000 worth of shares (357,143 units at $1.40), increasing direct ownership by 90% to 753,095 units

      4 - Ensysce Biosciences, Inc. (0001716947) (Issuer)

      2/1/23 6:06:45 PM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chang William H

      4 - Ensysce Biosciences, Inc. (0001716947) (Issuer)

      6/27/22 5:47:22 PM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENSC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Ensysce Biosciences Inc.

      SC 13G - Ensysce Biosciences, Inc. (0001716947) (Subject)

      11/14/24 5:52:56 PM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ensysce Biosciences Inc.

      SC 13G - Ensysce Biosciences, Inc. (0001716947) (Subject)

      11/6/24 4:15:58 PM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ensysce Biosciences Inc.

      SC 13G - Ensysce Biosciences, Inc. (0001716947) (Subject)

      10/29/24 5:27:56 PM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENSC
    Leadership Updates

    Live Leadership Updates

    See more

    $ENSC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ENSC
    SEC Filings

    See more

    $ENSC
    Financials

    Live finance-specific insights

    See more

    $ENSC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ensysce Biosciences Announces Appointment of Dr. Nily Osman as Chief Medical Officer

      SAN DIEGO, CA / ACCESSWIRE / April 18, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a current focus on reducing abuse and overdose, today announced the appointment of Dr. Nily Osman as Chief Medical Officer effective April 18, 2022. Dr. Osman will succeed Dr. William Schmidt as he transitions to Senior VP of Clinical Development and continues his role on the Company's clinical advisory board.Dr. Osman, a highly versatile board-certified neurologist, migraine and pain specialist, has over ten years of experience in both R&D and

      4/18/22 4:05:00 PM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ensysce Biosciences Appoints Industry Veteran Lee Rauch to Board of Directors

      SAN DIEGO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a focus on reducing abuse and overdose while providing relief for those with severe pain, today announced that Lee Rauch has been appointed to the Company's board of directors. Ms. Rauch, an experienced Chief Executive Officer and Strategy Advisor, has served both public and private companies. During her near 40-year career, Ms. Rauch successful built companies ranging in focus from pre-clinical research to advanced clinical development, took

      2/8/22 4:01:00 PM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ensysce Biosciences Grows its Management Team with Appointment of Dr. Linda Pestano as Chief Development Officer

      SAN DIEGO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC, OTC:ENSCW), a clinical stage biotech company with proprietary technology platforms to reduce the economic and social burden of prescription drug abuse and overdose, has appointed Linda Pestano, PhD, Chief Development Officer effective October 15, 2021. Dr. Pestano has worked through her career to guide the development of novel therapeutics to improve patient outcomes and quality of life. Dr. Pestano received her PhD from Tuffs University and undertook a Post-Doctoral Fellowship with Dana Farber Cancer Institute at the Harvard Medical School in Boston. Her early research was vi

      10/26/21 8:00:00 AM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lake Street initiated coverage on Ensysce Biosciences with a new price target

      Lake Street initiated coverage of Ensysce Biosciences with a rating of Buy and set a new price target of $4.00

      11/30/21 10:47:43 AM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Ensysce Biosciences Inc.

      SCHEDULE 13G/A - Ensysce Biosciences, Inc. (0001716947) (Subject)

      5/15/25 4:30:09 PM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Ensysce Biosciences Inc.

      10-Q - Ensysce Biosciences, Inc. (0001716947) (Filer)

      5/13/25 4:20:32 PM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ensysce Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Ensysce Biosciences, Inc. (0001716947) (Filer)

      5/13/25 4:15:12 PM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

      Corporate Update Call to be Held Thursday, March 21, 2024 at 11:00am ET to Discuss Recent FDA Breakthrough Therapy Designation and Phase 3 Clinical PlansSAN DIEGO, CA / ACCESSWIRE / March 15, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today reported financial results for the fourth quarter and full year of 2023.Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "We are proud of the significant progress Ensysce has made in 2023 both operationally and clinically for our lead pain therapeutic, PF614, and our overdose protection product, PF614-MPAR.

      3/15/24 8:00:00 AM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ensysce Biosciences Announces Updated Investor Presentation Available Via Investor Relations Website

      ~ Reminder: Corporate Update Conference Call to be Held Today at 11:00am ET ~SAN DIEGO, CA / ACCESSWIRE / April 11, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, today announced an updated investor presentation has been posted to the Company's investor relations website. As a reminder, the Company will be holding a corporate update conference call today, Tuesday, April 11, 2023, at 11:00am ET.Corporate Update Conference CallDate: Tuesday, April 11, 2023Time: 11:00am ETU.S. Dial-in: 1-877-407-0792International Dial-in: 1-201-689-8263Webcast: ENSC Corporate Upd

      4/11/23 8:10:00 AM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of Its Common Stock

      SAN DIEGO, CA / ACCESSWIRE / February 1, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that its Board of Directors has declared a dividend of 0.001 of a share of newly-designated Series A Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on February 13, 2023. The outstanding shares of Series A Preferred Stock will vote together with the outstanding shares of the Company's common stock, as a single class, excl

      2/1/23 8:05:00 AM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

      New York, NY, March 13, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on Ensysce Biosciences, Inc. (NASDAQ:ENSC). The update note includes information on Ensysce Biosciences' business model, services, industry, financial results, valuation, and risks. The update note is available below. Ensysce March 2025 Update Note    Highlights from the note include:                                               Ensysce Biosciences Advances Strategic Initiatives and Clinical Programs: Ensysce Biosciences reported robust operational advancements for the fiscal year ended December 31

      3/13/25 8:00:00 AM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

      NEW YORK, March 3, 2025 /PRNewswire/ -- Today's Marketplace (TMP) is proud to announce a featured interview with Ensysce Biosciences (NASDAQ:ENSC) CEO Dr. Lynn Kirkpatrick and Dr. Neel Pathak, DS, Program Director with Creighton University. The doctors joined TMP's host Jane King to discuss the ongoing issues with opioids for pain management and how "clever chemistry" is being used to introduce safer opioids that are less prone to accidental overdose and abuse. "Our team uses what I like to call 'clever chemistry' to create the next generation of opioids."The full interview can be viewed online here. "[Unfortunately,] opioids are still being prescribed for pain

      3/3/25 9:43:00 AM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

      ~ Positive Phase 1b Data Confirms Overdose Protection for Highest Dosage Form of PF614-MPAR ~ SAN DIEGO, CA / ACCESS Newswire / January 22, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced interim data from its second clinical trial to evaluate PF614-MPAR for overdose protection. Clinical study PF614-MPAR-102, ‘A Single and Multiple Dose Study to Evaluate the Pharmacokinetics of Oxycodone and PF614 when PF614 Capsule is Co‑Administered with Nafamostat as a Combination of Immediate Release Solutio

      1/22/25 8:00:00 AM ET
      $ENSC
      Biotechnology: Pharmaceutical Preparations
      Health Care